Key result
Perindopril, verapamil, and atenolol similarly reduce central systolic pressure in Marfan syndrome.
Why the study?
Do atenolol, perindopril, and verapamil reduce central aortic pressure and improve large artery function in patients with Marfan syndrome?
RCT (n=18)
double-blind
randomised
Do atenolol, perindopril, and verapamil reduce central aortic pressure and improve large artery function in patients with Marfan syndrome?
Atenolol, perindopril, and verapamil all effectively reduce central systolic pressure in Marfan syndrome, but atenolol uniquely slows heart rate and delays aortic wave travel, supporting its continued use.
Answers are grounded in this paper and cite their sources.
Supports equivalent central pressure reduction with any of the three agents in Marfan syndrome; extends options beyond beta-blockers while confirming class similarity.
BACKGROUND: Aortic dilatation is the main therapeutic target in patients with Marfan syndrome. Standard treatment with a β-blocker may not lower central pulse pressure - the major objective - because it does not do so in hypertension, unlike angiotensin-converting enzyme inhibitors and calcium-channel blockers. We therefore performed a prospective, randomised, double-blind, crossover trial to compare the effects of these three agents on large artery function and central aortic pressure in patients with Marfan syndrome. METHODS AND RESULTS: Eighteen patients had applanation tonometry, pulse wave analysis and echocardiography, before and after atenolol 75 mg, perindopril 4 mg and verapamil 240 mg, each given for 4 weeks, in a random order, with 2 weeks between medications. Fourteen patients completed the study. Within-drug comparisons demonstrated that perindopril (-10·3 mmHg, P = 0·002), verapamil (-9·2 mmHg, P = 0·003) and atenolol (-7·1 mmHg, P = 0·01) all reduced central systolic pressure and brachial pressure; central changes were least, and peripheral changes greatest with atenolol but between-drug comparisons (analysis of covariance) were not significant. There was a trend for augmentation to be reduced by perindopril (-6·3%, P = 0·05), verapamil (-5·5%, P = 0·07) and atenolol (-3·2%, P = 0·09). Only atenolol reduced heart rate (by 16%) and delayed expansion in the arch and abdominal aorta (by 8% and 11%) (P < 0·001, P < 0·01 and P < 0·05, respectively, for between-drug comparisons). CONCLUSIONS: Perindopril, verapamil and atenolol all reduced peripheral and central systolic pressure. As atenolol slowed heart rate and delayed aortic wave travel, β-blockade may have a continuing role in the treatment of patients with Marfan syndrome.
No takes yet. Share an insight, caveat, or question.
Williams et al. (2012) conducted an RCT in Marfan syndrome (n=18). Atenolol, perindopril, and verapamil vs. Active comparators (crossover) was evaluated on Central systolic pressure. Perindopril, verapamil, and atenolol all reduced central systolic pressure in Marfan syndrome, with no significant differences between drugs.
Synapse has enriched 10 related papers. Consider them for comparative context: